![Beth Weinberg](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profiel
Beth Weinberg is currently Chief Regulatory & Safety Officer at Apnimed, Inc. Former positions include Vice President & Head-Regulatory at Angion Biomedica Corp., VP, Head-Regulatory Affairs & Quality at Metavant Sciences, Inc., and Senior Vice President-Regulatory Affairs at CARA Therapeutics, Inc. from 2022 to 2024.
Education includes undergraduate studies at Butler University and Bradley University.
Actieve functies van Beth Weinberg
| Bedrijven | Functie | Begin |
|---|---|---|
| APNIMED, INC. | Algemeen Adviseur | - |
Eerdere bekende functies van Beth Weinberg
| Bedrijven | Functie | Einde |
|---|---|---|
| CARA THERAPEUTICS, INC. | Algemeen Adviseur | 01-07-2024 |
| ANGN BIOM | Algemeen Adviseur | - |
Metavant Sciences, Inc.
 Metavant Sciences, Inc. Part of Roivant Sciences Ltd., Metavant Sciences, Inc. is a biotechnology company founded in 2014 with the goal of improving the lives of patients by accelerating the development and commercialization of medicines that matter. The company builds nimble subsidiaries called "Vants" to develop and commercialize its medicines and technologies. Metavant Sciences, Inc. has a diverse pipeline of investigational drugs across its family of companies, including Immunovant, Dermavant, and Priovant. Immunovant focuses on developing potentially transformative therapies for autoimmune diseases, while Priovant is developing targeted therapies for severe autoimmune diseases. The company is based in New York. | Algemeen Adviseur | - |
Opleiding van Beth Weinberg
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
26
Eerstegraads connecties
6
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 6 |
|---|---|
CARA Therapeutics, Inc.
 CARA Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes new chemical entities designed to fundamentally change the way acute pain, chronic pain and pruritus are managed | Health Technology |
Butler University
 Butler University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bradley University
 Bradley University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Angion Biomedica Corp.
 Angion Biomedica Corp. Pharmaceuticals: MajorHealth Technology Provides biopharmaceutical products | Health Technology |
Apnimed, Inc.
 Apnimed, Inc. BiotechnologyHealth Technology Engages in developing and commercializing of proprietary therapeutics for sleep apnea & breathing diseases | Health Technology |
Metavant Sciences, Inc.
Metavant Sciences, Inc. Part of Roivant Sciences Ltd., Metavant Sciences, Inc. is a biotechnology company founded in 2014 with the goal of improving the lives of patients by accelerating the development and commercialization of medicines that matter. The company builds nimble subsidiaries called "Vants" to develop and commercialize its medicines and technologies. Metavant Sciences, Inc. has a diverse pipeline of investigational drugs across its family of companies, including Immunovant, Dermavant, and Priovant. Immunovant focuses on developing potentially transformative therapies for autoimmune diseases, while Priovant is developing targeted therapies for severe autoimmune diseases. The company is based in New York. |
